GGrantIndex
← Search

PHASE I STUDY OF SEQUENTIAL CPT 11 &MITOMYCIN C

$16,409M01FY2000RRNIH

University Of Texas Hlth Sci Ctr San Ant, San Antonio TX

Investigators

Linked publications & trials

Abstract

The objectives of this protocol are to determine the maximum tolerated dose of Mitomycin C (MMC) when given in combination with CPT-11, to determine if the pharmacokinetic behavior of CPT-11 is altered prior to administration of MMC, to determine the effect of CPT-11 and MMC on the expression of DT-Diaphorase and the Topo I gene, and to evaluate the antitumor activity of the combination.

View original record on NIH RePORTER →